Table 6.
Pharmacokinetic parameters of lycopene in rat plasma following oral administration.
| Parameters | LOO | Optimized LME |
|---|---|---|
| AUC(0–∞) (h·ng/mL) | 2270.96 ± 455.46 | 4775.93 ± 634.00** |
| Cmax (ng/mL) | 121.32 ± 13.47 | 220.48 ± 30.84** |
| Tmax (h) | 6.33 ± 0.82 | 7.67 ± 0.82 |
| t1/2 (h) | 13.75 ± 1.10 | 17.01±2.61* |
| MRT(0–∞) (h) | 21.49 ± 1.11 | 25.94±3.70* |
| CL (L/h/kg) | 3.64 ± 0.74 | 1.70 ± 0.23** |
| Relative bioavailabilitya | – | 210.30% |
LOO: lycopene dissolved in olive oil; LME: lycopene-loaded microemulsion; AUC: area under the concentration-time curve; Cmax: peak concentration; Tmax: time to reach peak concentration; t1/2: half-life; MRT: mean residence time; CL: plasma clearance.
Each value is the mean ± SD of six rats. Statistical significances were performed as follows: t1/2, MRT and CL: one-way ANOVA; AUC and Cmax: one-way ANOVA following logarithmic transformation; Tmax: Mann–Whitney U-test.
*p < .05, **p < .01 compared with LOO.
a
LOO as reference.